IGFBP-5 acts as a tumor suppressor by inhibiting angiogenesis, providing first evidence of its antiangiostatic role.
Answers are grounded in this paper and cite their sources.
Provides preclinical support for IGFBP-5 as an angiogenesis inhibitor in ovarian cancer; leaves open clinical translation.
Insulin-like growth factor-binding protein-5 (IGFBP-5) is one of the six members of IGFBP family, important for cell growth control, induction of apoptosis and other IGF-stimulated signaling pathways. In this study, we focused on characterizing the specific function of IGFBP-5 as novel antiangiostatic factor. Overexpression of IGFBP-5 suppressed the tube formation as well as the biological functions of angiostatic activity in vivo. This result is due to the reduced expressions of phosphorylated protein kinase B and phosphorylated endothelial NO synthase, which plays important roles in the regulation of angiogenesis when stimulated by vascular endothelial growth factor. Further, IGFBP-5 expression prevented tumor growth and inhibited tumor vascularity in a xenograft model of human ovarian cancer. These results are the first evidence showing that IGFBP-5 plays a role as tumor suppressor by inhibiting angiogenesis.
No takes yet. Share an insight, caveat, or question.
Rho et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: